Immune-Related Adverse Events for GI Toxicity - Hepatitis
ورودیهای بالینی بیمار
حداقل ۵ — حداکثر ۵۰۰۰ • واحد: U/L
حداقل ۲۰ — حداکثر ۸۰ • واحد: U/L
حداقل ۵ — حداکثر ۵۰۰۰ • واحد: U/L
حداقل ۲۰ — حداکثر ۸۰ • واحد: U/L
حداقل ۰.۱ — حداکثر ۵۰ • واحد: mg/dL
حداقل ۰.۸ — حداکثر ۲ • واحد: mg/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Grade 11–1
- Grade 22–2
- Grade 33–3
- Grade 44–4
The Immune-Related Adverse Events for GI Toxicity - Hepatitis calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include ast level. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.
Clinical Indication
The Immune-Related Adverse Events for GI Toxicity - Hepatitis is indicated for bedside clinical practice to support Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Liver chemistries should be repeated before each ICI treatment cycle.
CTCAE grading based on AST/ALT fold increase over ULN and total bilirubin fold increase over ULN: Grade 1: AST/ALT 1-3× ULN OR bilirubin 1-1.5× ULN; Grade 2: AST/ALT 3-5× ULN OR bilirubin 1.5-3× ULN; Grade 3: AST/ALT 5-20× ULN OR bilirubin 3-10× ULN; Grade 4: AST/ALT >20× ULN OR bilirubin >10× ULN OR hepatic decompensation
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| ast_level | float | Yes | Aspartate aminotransferase (AST) level in U/L. Key parameter for hepatitis grading. Normal range typically 10-40 U/L depending on laboratory. Used to calculate AST fold increase over upper limit of normal (ULN)(U/L) |
| ast_uln | float | Yes | Upper limit of normal (ULN) for AST at your laboratory. Typically 40 U/L but may vary by institution. Required to calculate fold increase over normal values for CTCAE grading(U/L) |
| alt_level | float | Yes | Alanine aminotransferase (ALT) level in U/L. Key parameter for hepatitis grading. Normal range typically 7-56 U/L depending on laboratory. Used to calculate ALT fold increase over upper limit of normal (ULN)(U/L) |
| alt_uln | float | Yes | Upper limit of normal (ULN) for ALT at your laboratory. Typically 40-56 U/L but may vary by institution. Required to calculate fold increase over normal values for CTCAE grading(U/L) |
| total_bilirubin | float | Yes | Total bilirubin level in mg/dL. Critical parameter for severe hepatitis grading. Normal range typically 0.2-1.2 mg/dL. Elevated levels indicate hepatocellular injury or cholestasis(mg/dL) |
| bilirubin_uln | float | Yes | Upper limit of normal (ULN) for total bilirubin at your laboratory. Typically 1.0-1.2 mg/dL but may vary by institution. Required to calculate fold increase for CTCAE grading(mg/dL) |
| hepatic_decompensation | string | Yes | Presence of signs of hepatic decompensation including ascites, hepatic encephalopathy, coagulopathy, or variceal bleeding. Any decompensation warrants Grade 4 classification regardless of laboratory values |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Grade 1 | Mild - AST/ALT 1-3× ULN OR total bilirubin 1-1.5× ULN |
| 2–2 | Grade 2 | Moderate - AST/ALT 3-5× ULN OR total bilirubin 1.5-3× ULN |
| 3–3 | Grade 3 | Severe - AST/ALT 5-20× ULN OR total bilirubin 3-10× ULN |
| 4–4 | Grade 4 | Life-threatening - AST/ALT >20× ULN OR total bilirubin >10× ULN OR hepatic decompensation |
Evidence-Based References (EBM)
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
- Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
- Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.DOI: 10.1001/jamaoncol.2018.3923
- De Martin E, Michot JM, Papoular B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033.DOI: 10.1016/j.jhep.2018.01.033
Related calculators
- Immune-Related Adverse Events for GI Toxicity - Colitis
- Immune-Related Adverse Events for Lung Toxicity - Pneumonitis
- Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism
- Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus
- Immune-Related Adverse Events for Renal Toxicities - Nephritis